Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yiyi Yu

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 15, 2018
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world studyXi Cheng, Shan Yu, Yan Wang, et al.
Journal of the National Cancer Institute|August 11, 2019
Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of GlioblastomaYingying Lin, Keman Liao, Yifeng Miao, et al.
Oncotarget|February 11, 2016
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort studyQingyang Feng, Ye Wei, Li Ren, et al.
The Oncologist|June 27, 2019
Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC StudyYiyi Yu, Yong Fang, Zhenbin Shen, et al.
Journal of Natural Products|January 5, 2022
Targeted Discovery of Amantamide B, an Ion Channel Modulating Nonapeptide from a South China Sea <i>Oscillatoria</i> CyanobacteriumTe Li, Chuchu Xi, Yiyi Yu, et al.
Cancer Communications (London, England)|July 19, 2022
Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomachMengxuan Zhu, Erbao Chen, Shan Yu, et al.
Cell Death & Disease|July 13, 2024
IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophagesJiayu Zhang, Yu Dong, Shan Yu, et al.
Nature Communications|October 15, 2024
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trialJing Wu, Shilong Zhang, Shan Yu, et al.
Nature Communications|August 23, 2024
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 studyXiaojing Xu, Luoyan Ai, Keshu Hu, et al.
Oncogenesis|September 21, 2022
Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathwayMengling Liu, Xiaojing Xu, Ke Peng, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 15, 2018
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world studyXi Cheng, Shan Yu, Yan Wang, et al.
Journal of the National Cancer Institute|August 11, 2019
Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of GlioblastomaYingying Lin, Keman Liao, Yifeng Miao, et al.
Oncotarget|February 11, 2016
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort studyQingyang Feng, Ye Wei, Li Ren, et al.
The Oncologist|June 27, 2019
Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC StudyYiyi Yu, Yong Fang, Zhenbin Shen, et al.
Journal of Natural Products|January 5, 2022
Targeted Discovery of Amantamide B, an Ion Channel Modulating Nonapeptide from a South China Sea <i>Oscillatoria</i> CyanobacteriumTe Li, Chuchu Xi, Yiyi Yu, et al.
Cancer Communications (London, England)|July 19, 2022
Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomachMengxuan Zhu, Erbao Chen, Shan Yu, et al.
Cell Death & Disease|July 13, 2024
IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophagesJiayu Zhang, Yu Dong, Shan Yu, et al.
Nature Communications|October 15, 2024
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trialJing Wu, Shilong Zhang, Shan Yu, et al.
Nature Communications|August 23, 2024
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 studyXiaojing Xu, Luoyan Ai, Keshu Hu, et al.
Oncogenesis|September 21, 2022
Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathwayMengling Liu, Xiaojing Xu, Ke Peng, et al.
Pageof 13